Stay updated with breaking news from Eric Easom. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Phase 2/3 trial in treatment-refractory Mycobacterium avium Complex continues with Phase 2 topline results expected in summer 2024 and Phase 3 enrollment pause in place during continued analysis of...
MENLO PARK - AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today...
AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that...
Enrollment well underway in Phase 3 part of pivotal Phase 2/3 study of epetraborole in treatment-refractory Mycobacterium avium complex lung disease On track to announce Phase 2 clinical data...
AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that...